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suggest that a common pathogenetic mechanism might accountPlasma phospholipid arachidonic acid content and calcium me-
for the several forms of hypercalciuria detected in idiopathictabolism in idiopathic calcium nephrolithiasis.
calcium nephrolithiasis.Background. Reports of an increase in plasma and erythro-
cyte phospholipid arachidonic acid content and in urinary prosta-
glandin E2 (PGE2) excretion in patients with idiopathic calcium
nephrolithiasis suggested their crucial role in the pathogenesis
We recently described an increased arachidonic acidof hypercalciuria, a well-known risk factor for lithogenesis.
(AA) level in the plasma and erythrocyte phospholipidsMethods. To confirm this hypothesis, 15 healthy subjects
and 20 nephrolithiasis patients were evaluated for plasma phos- of patients with idiopathic calcium nephrolithiasis (ICN)
pholipid polyunsaturated fatty acid content and PGE2 concen- [1]. This finding followed previous literature reports of an
tration, serum parathyroid hormone, 25 hydroxyvitamin D3, alteration in urine excretion of prostaglandins E2 (PGE2),1,25-dihydroxyvitamin D3, and bone-specific alkaline phospha-
the main metabolite of membrane phospholipid AA, intase levels, as well as urinary excretion of calcium, biochemical
markers of bone resorption (hydroxyproline and crossLaps), ICN patients [2–5]. In the light of the effects of dietary-
and intestinal calcium absorption. Furthermore, the effect of induced phospholipid AA level modifications on cellular
a 30-day fish-oil diet supplementation on the previously men- and renal calcium transport [6, 7] and the important
tioned parameters was investigated in the patients.
hypercalciuric effect of PGE2 [5, 8, 9], we advanced thatResults. At baseline, patients compared with controls showed
phospholipid AA content might have a crucial role in thehigher levels of plasma phospholipid arachidonic acid content
(P 5 0.002), PGE2 (P 5 0.0004), serum 25-vitamin D3 (P 5 pathogenesis of hypercalciuria, a well-known risk factor
0.001), and 1,25-vitamin D3 (P 5 0.001), urinary excretion of for calcium lithogenesis [1, 10, 11]. To confirm this hy-
calcium (P 5 0.001), hydroxyproline (P 5 0.007), and crossLaps pothesis, in a group of ICN patients, we evaluated the(P 5 0.019), as well as intestinal calcium absorption (P 5 0.03
relationship between plasma phospholipid AA content,at 60 min). Fish oil supplementation induced a reduction in
calcium-regulating hormones, and intestinal, renal, andthe plasma phospholipid arachidonic acid level (P , 0.0001),
and except for serum concentrations of 25-vitamin D3, normal- bone calcium metabolism alterations, which were ob-
ized baseline blood and urinary parameters, including intestinal served to constitute the main causes of idiopathic hyper-
calcium absorption. A close correlation between plasma PGE2 calciuria in calcium nephrolithiasis [12].and serum 1,25-vitamin D3 (P 5 0.004) and between phospho-
lipid arachidonic acid and intestinal calcium absorption (P 5
0.0002) and calciuria (P 5 0.007) was observed, as well as
METHODSbetween urine excretion of crossLaps and hydroxyproline (P ,
0.0001), crossLaps and calcium (P , 0.0001), and hydroxypro- Study patients
line and calcium (P , 0.0001).
The study was conducted in 20 recurrent idiopathicConclusions. These findings indicate that the phospholipid
calcium oxalate stone formers (male 17 and female 3;arachidonic acid content anomaly could represent the primary
event responsible for the mosaic of metabolic and clinical alter- median age 36 years; range, 23 to 56) consecutively se-
ations that are distinctive features of renal stone formers, and lected among those attending our outpatient clinic and
fulfilling the previously described criteria for ICN [1, 13].
Fifteen healthy staff members (male 12 and female 3;Key words: calciotropic hormones, hypercalciuria, lithogenesis, renal
stone formers, kidney stones. median age 34 years; range, 22 to 52) served as control
subjects; none had a family or personal history of nephro-
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or immunologic disease. All gave their informed consent (AUC at 30, 60, and 240 minutes) by the trapezoid
to the study, according to the Helsinki Declaration. No method, and Sr absorption was expressed as mmol/L21/
patient or control subject had been placed on any type minute; the other calculated the fractional absorption
of therapeutic regimen in the eight weeks before the study, (FA) of the administered dose (FA at 30, 60, 240 min-
and in particular, none was taking any lipid-lowering drug utes), considering 15% of body weight as the distribution
or other agent known to affect lipid metabolism. In the volume [15, 16].
eight weeks preceding the study, all participants were
Statistical analysisasked to consume a diet that matched their usual caloric
content and macronutrient distribution. Seventeen of the Statistical evaluation was carried out with Student’s
patients agreed to continue the study and received one t-test for paired and unpaired variables and determina-
capsule (Seacort-SPA-Italy) containing 850 mg of v-3 tion of the r coefficient for linear correlation. The rela-
polyunsaturated fatty acid ethyl esters (fish oil) three tionship between some parameters as dependent vari-
times daily for 30 days, as previously reported [1]. ables and others as independent variables was analyzed
by a stepwise multiple regression model. Statistical sig-
Analytical procedures
nificance was defined as a P value less than 0.05.
At the beginning of the study, all participants fasted
from 8 p.m. of the preceding evening, and the following
RESULTSparameters were determined: creatinine, uric acid, urea
nitrogen, electrolyte concentration, lipid analysis, and Findings at baseline and after fish oil supplementation
the phospholipid polyunsaturated fatty acid content [1], are summarized in Table 1. At baseline, the patients versus
plasma PGE2 (PerSective Diagnostics, Cambridge, MA, control subjects showed an increase in plasma phospho-
USA), serum bone-specific alkaline phosphatase (BAP; lipid AA content and PGE2 values and in serum 25-Vit D
Boehringer Mannheim, Milan, Italy), intact parathyroid and 1,25-Vit D concentrations; all the other parameters,
hormone (PTH; Bio-Rad Laboratories, Milan, Italy), 25- including age, sex ratio, body mass index (BMI), and
hydroxyvitamin D3 (25-Vit D; Buhlmann Laboratories, plasma lipid values, did not differ between the two groups.
Allshwil, Switzerland), and 1,25-dihydroxyvitamin D3 At the urine level, the patients presented an increased
(1,25-Vit D; Nichols Institute, Diagnostics, San Juan Cap- excretion of calcium, CTX, and HP. Moreover, the pa-
istrano, CA, USA). Each analysis was carried out in tients showed an increase in intestinal absorption of Sr
duplicate and was expressed as the mean of two determi- that was significant at 30 and 60 minutes (both expressed
nations. On the test day, after eight weeks of controlled as FA and AUC) and at 240 minutes (expressed as AUC;
diet, fasting urines were collected for two hours from Table 2). Mean T-scores in the two groups showed no
7 a.m. to 9 a.m. for assay of creatinine, urea nitrogen, significant difference; six patients had the T-scores that
calcium, and phosphorus, as well as some biochemical were a little lower, but not more than 10%.
markers of bone turnover, including hydroxyproline The effects of fish oil supplementation are reported
(HP) (Beckman Analytical, Milan, Italy) and crossLaps in Table 1. This regime induced a reduction in the plasma
(CTX; Cis Diagnostici, Vercelli, Italy). CTX measures phospholipid content of linoleic and AA and an increase
the degradation products of type 1 collagen C-telopep- in eicosapentaenoic and docosahexaenoic acids. More-
tide and represents a specific marker of bone resorption
over, the fish oil supplementation was able to modify
[14]. All determinations were carried out in duplicate and
the blood and urine parameters that were altered atwere expressed as the mean for urine creatinine. Bone
baseline. It lowered calcium-regulating hormones, PGE2mineral density (BMD) of the lumbar spine (L2-L4)
and 1,25-Vit D, but not 25-Vit D values, and reducedwas assessed by dual-energy x-ray densitometer (Hologic
intestinal Sr absorption (Table 2), urine calcium excretionQDR 1000, Boston, MA, USA). BMD values were ex-
(Fig. 1), and the biochemical markers of bone remodel-pressed as the number of standard deviations from the
ing, such as serum BAP and urine HP and CTX. Nomean of the normal young Caucasian population (T-score).
correlation was observed between the plasma phospho-Blood and urine parameters were re-evaluated at the
lipid AA content and PGE2 values (r 5 0.14). In contrast,end of the v-3 fatty acid supplementation trial.
a direct significant correlation between plasma PGE2 and
Intestinal strontium absorption test serum 1,25-Vit D values emerged (Fig. 2), as well as a
close correlation between the phospholipid AA levelThe strontium (Sr) oral test was performed to deter-
and intestinal Sr absorption (Table 3).mine intestinal calcium absorption as previously described
Moreover, a direct correlation between urine excre-[15] in 11 controls and in 17 patients before and after v-3
tion of CTX and HP (Fig. 3), CTX and calcium (Fig. 4),polyunsaturated fatty acid supplementation; no food was
and HP and calcium (Fig. 5), and between plasma phos-supplied during the Sr test. Sr absorption was expressed
pholipid AA content and calciuria (Fig. 6) was observed.by two different methods. The first determined the incre-
mental area under the serum concentration-time curve Stepwise multiple analysis showed that plasma phospho-
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Table 1. Biochemical parameters of control subjects and patients before and after fish oil supplementation
Patients
Controls Before After P valuesa P valuesb P valuesc
Plasma fatty acid %
C18:0 (Stearic) 13.5060.80 13.7361.29 14.1860.99 0.5474 0.0627 0.0406
C18:2 n-6 (Linoleic) 25.7562.55 24.6762.39 21.3563.02 0.2076 0.0001 0.0001
C20:4 n-6 (Arachidonic) 10.0460.91 11.1761.08 9.5861.17 0.0024 ,0.0001 0.2336
C20:5 n-3 (EPA) 0.6360.16 0.7760.29 4.8860.88 0.1219 ,0.0001 ,0.0001
C22:6 n-3 (DHA) 3.8260.68 3.3760.94 6.4461.02 0.1177 ,0.0001 ,0.0001
Plasma phospholipids mg/dL 200.10625.10 201.40630.90 203.44628.02 0.8943 0.6656 0.7259
Plasma PGE2 ng/L 111.73637.66 163.94639.24 95.82648.23 0.0004 ,0.0001 0.3109
Serum PTH ng/L 32.93610.53 31.10611.35 37.41615.99 0.6290 0.0951 0.3636
Serum 25-vitamin D nmol/L 46.96611.71 62.55614.24 65.29620.27 0.0015 0.6038 0.0043
Serum 1,25 vitamin D pmol/L 44.45610.23 60.15615.58 44.33621.67 0.0018 0.0085 0.9848
Serum 25-vitamin D/1,25-vitamin D 1.1560.40 1.2860.53 2.0661.49 0.4355 0.0228 0.0291
Serum Calcium mmol/L 2.3460.07 2.2960.11 2.3160.09 0.1144 0.6049 0.3131
Serum Phosphorus mmol/L 1.2960.15 1.1960.18 1.2260.23 0.1155 0.6632 0.3300
Serum BAP U/L 28.10610.50 30.23616.34 26.94616.21 0.6623 0.0025 0.8146
Urinary urea mmol/mmol Cr 12.8462.45 13.9163.65 13.0164.00 0.3345 0.7088 0.8837
Urinary calcium mmol/mmol Cr 0.0860.03 0.1360.05 0.0860.04 0.0011 0.0348 0.9342
Urinary Phosphorus mmol/mmol Cr 0.3560.05 0.2860.06 0.3160.15 0.0017 0.1361 0.3802
Urinary CTX lg/mmol Cr 259.22657.76 323.82688.24 217.45696.58 0.0192 0.0179 0.1543
Urinary HP lmol/mmol Cr 12.0065.21 18.0166.96 11.1267.66 0.0078 0.0395 0.7102
Plus-minus values are means 6 SD. Abbreviations are: P-Fatty acid, the percentage of fatty acids in plasma phospholipids; EPA and DHA, eicosapentaenoic and
docosahexaenoic acids; BAP serum bone-specific alkaline phosphatase; CTX, crossLaps; HP, hydroxyproline.
a Comparison between patients (before) and control subjects (unpaired t-test)
b Comparison between patients before and after treatment (paired t-test)
c Comparison between patients (after) and control subjects (unpaired t-test)
Table 2. Strontium (Sr) oral load test in control subjects and patients before and after fish oil supplementation
Patients
Controls Before After P valuesa P valuesb P valuesc
Sr-FA 30 min 13.9866.14 18.9265.91 12.5365.29 0.0420 0.0002 0.5112
Sr-FA 60 min 22.8467.12 29.3168.00 24.7566.85 0.0380 0.0040 0.4836
Sr-FA 240 min 27.55610.72 30.8768.10 30.38610.38 0.3589 0.7951 0.4911
Sr-AUC 30 min 0.4260.19 0.5760.17 0.3860.16 0.0406 0.0002 0.5102
Sr-AUC 60 min 1.5460.53 2.0360.60 1.5160.48 0.0354 0.0001 0.8736
Sr-AUC 240 min 10.6863.57 12.9563.84 11.5163.29 0.1279 0.0182 0.5346
Plus-minus values are means 6 SD. Sr-FA and Sr-AUC denote the intestinal Sr absorption expressed by two ways (Methods).
a Comparison between patients (before) and control subjects (unpaired t-test)
b Comparison between patients before and after treatment (paired t-test)
c Comparison between patients (after) and control subjects (unpaired t-test)
Fig. 2. Relationship between plasma prostaglandin E2 (PGE2) and se-
rum 1,25-vitamin D3 (1,25-Vit D) concentration in control subjects (s)Fig. 1. Effects of fish oil administration on urine calcium excretion
(P 5 0.35). and patients (d) (r 5 0.47, P 5 0.0044).
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Table 3. Relationships between plasma phospholipid arachidonic
acid content (P-AA) and intestinal strontium absorption rate
expressed by fractional absorption and area under the serum
concentration curve (AUC) procedures (Methods section)
r P values
P-AA/Sr-FA 30 min 0.41 0.0292
P-AA/Sr-FA 60 min 0.65 0.0002
P-AA/Sr-FA 240 min 0.66 0.0001
P-AA/Sr-AUC 30 min 0.41 0.0292
P-AA/Sr-AUC 60 min 0.54 0.0028
P-AA/Sr-AUC 240 min 0.68 0.0001
Fig. 4. Relationship between urine crossLaps (CTX) and calcium ex-
cretion in control subjects (s) and patients (d) (r 5 0.75, P , 0.0001).
Fig. 3. Relationship between urine excretion of crossLaps (CTX) and
hydroxyproline (HP) in control subjects (s) and patients (d) (r 5 0.72,
P , 0.0001).
Fig. 5. Relationship between urine HP and calcium excretion in sub-
lipid AA content and serum 1,25-Vit D concentration were jects (s) and patients (d) (r 5 0.72, P , 0.0001).
the only statistically significant variables influencing intesti-
nal Sr absorption at 60 minutes (Table 4), and that the
calciuria was best explained by urine CTX and HP excre-
an epiphenomenon of a primary, as yet undefined gener-
tion, as well as intestinal calcium absorption (Table 5). alized disturbance of calcium metabolism [17–19]. As
1,25-Vit D plays a central role in calcium metabolism at
the intestinal, renal, and bone levels, a disorder in itsDISCUSSION
pathway was a most attractive hypothesis to explain theThe clinical and biochemical profiles of the patients
different forms of hypercalciuriua. Indeed, increased se-who constituted the basis of our study showed the typical
rum 1,25-Vit D levels have been observed in patientsfeatures of idiopathic calcium renal stone formers. In-
with hypercalciuria [17, 20–22] and have been confirmeddeed, besides the hypercalciuria, we observed an alter-
by our study. Considering the selection criteria we used,
ation in calcium-regulating hormones, such as serum lev- the difference in 1,25-Vit D levels between patients and
els of calcidiol and calcitriol, and an increase in intestinal controls in our study did not depend upon different sun-
calcium absorption and bone turnover, as documented light exposure times or other environmental factors.
by the Sr test and the urinary excretion of biochemical Moreover, calcitriol synthesis might be activated perhaps
markers of bone resorption (CTX and HP). via a yet uncharacterized disorder in phosphate metabo-
Hypercalciuria is the most common metabolic abnor- lism or, more simply, a mechanism(s) that up-regulates
mality in ICN. It appears to reflect a heterogeneous en- receptors for calcitriol. Both processes increase intestinal
tity and to result from a variety of causes, including calcium absorption and urinary calcium excretion, and
dietary calcium excess, intestinal calcium hyperabsorp- probably bone turnover as well [23–26]. However, most
tion, calcium renal leak, and bone loss [12]. The problem studies in this field have not yet reached definitive con-
is whether the several types of idiopathic hypercalciuria, clusions. In particular, it is not clear whether the disorder
including the absorptive, renal, and resorptive forms, in the 1,25-Vit D pathway is a primary one or secondary
to some other calcium metabolism defect. In our opinion,reflect a spectrum of independent calcium disorders or
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Table 5. Multivariate regression analysis of the relationship
between urine calcium excretion and other biochemical variables
Statistics
Variables b SE P values
U-Ca
U-CTX 0.452 (0.135) 0.0021
U-HP 0.407 (0.135) 0.0052
Sr-FA 60 min 0.265 (0.014) 0.0082
F527.844 R 2 50.73 P,0.0001
The analysis was carried out in 28 subjects (11 controls and 17 patients) and
is the result of a stepwise multiple regression by excluding the less significant
variables. Abbreviations are: CTX, crossLaps; HP, hydroxyproline; Sr-FA, 60
minutes of intestinal Sr absorption; b, standardized regression coefficient.
Fig. 6. Relationship between plasma phospholipid arachidonic acid of idiopathic hypercalciuria through different actions.(AA) content and calciuria in control subjects (s) and patients (d)
Indeed, an increase in phospholipid AA content deter-(r 5 0.44, P 5 0.0075).
mines a cascade of metabolic effects on calcium homeo-
stasis leading to hypercalciuria, essentially because of a
Table 4. Multivariate regression analysis of the relationship direct action of AA as second messenger on cellular
between intestinal strontium absorption rate (Sr-FA 60 min) and calcium transport [29] or through the PGE2/1,25-Vit Dother biochemical variables
pathway. PGE2, the main metabolite of AA, is known
Statistics to modulate renal calcium handling by inhibiting the
Variables b SE P values
Na/K/2 Cl cotransporter, whose activity is important in
Sr-FA 60 min driving calcium tubular reabsorption [5, 8] or by otherP-AA 0.666 (0.136) 0.0001
mechanisms [9]. Moreover, the effects of PGE2 on theS-1,25 Vit D 0.351 (0.121) 0.0239
F514.440 R 2 50.53 P,0.0001 activity of 1,a hydroxylase, the rate-limiting step in the
P-AA denotes the plasma phospholipid arachidonic acid content. The analysis formation of calcitriol, are well known [9], and seem
was carried out in 28 subjects (11 controls and 17 patients) and is the result of a to be confirmed by the direct correlation that emergedstepwise multiple regression by excluding the less significant variables. b denotes
standardized regression coefficient. between PGE2 and 1,25-Vit D values (Fig. 1) and the
results of fish oil supplementation, which showed a sig-
nificant decrease in 1,25-Vit D levels, but not in those
the present study provides new and important insights of its precursor 25-Vit D, leading to an increase in the
into the pathophysiology of idiopathic hypercalciuria be- calcidiol/calcitriol ratio. Excess calcitriol production was
cause it confirms our previous hypothesis of a causal shown to induce intestinal calcium hyperabsorption, and
link between membrane phospholipid AA levels and the reduced calcium tubular reabsorption [9]. Interestingly,
calcium-related abnormalities frequently occurring in a positive correlation was observed between plasma
ICN patients [1, 10, 11]. This statement is supported by phospholipid AA level and intestinal Sr absorption (Ta-
the results observed at baseline and is reinforced by ble 3). Moreover, multiple regression analysis disclosed
the effects of polyunsaturated fatty acid administration. that the plasma phospholipid AA content and serum
Indeed, we found an increase in the plasma phospholipid 1,25-Vit D levels were the only statistically significant
AA content, which agrees well with our previous finding and independent variables influencing intestinal Sr ab-
in another group of nephrolithiasic patients [1]. As ex- sorption (Table 4), thus suggesting a direct and indepen-
pected [1, 27], and also confirming good dietary compli- dent effect of AA, besides the PGE2/1,25-Vit D mecha-
nism, on intestinal calcium transport.ance, fish oil supplementation was able to induce a reduc-
tion in the plasma phospholipid AA level. Moreover, it Regarding the possible link between phospholipid AA
values and bone remodeling, it is noteworthy that PGE2demonstrated a hypocalciuric effect that is in agreement
with previous reports [1, 28]. This regimen also induced and 1,25-Vit D, besides their effects on renal and intesti-
nal calcium handling, also play a role in stimulating bonea reduction in PGE2 (the main metabolite of AA) and
calcitriol values, as well as in intestinal Sr absorption, resorption and could constitute an additional source of
urinary calcium in ICN [30]. The observations of primaryand a decrease in bone turnover, as documented by the
reduction in biochemical markers of bone resorption or secondary high bone turnover in some hypercalciuric
renal stone formers were confirmed by the present data.(urinary HP and CTX excretion) and bone formation
(serum BAP values). Indeed, we found an increase in specific biochemical
markers of bone resorption, a positive correlation be-Whatever the mechanism underlying the rise in the
phospholipid AA proportion, we suggested that this tween urine excretion of calcium, CTX, and HP (Figs.
3 and 4), and a simultaneous reversal effect of dietary fishanomaly could play a crucial role in the pathogenesis
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oil administration on calciotropic hormones, biochemical that of others [17, 18, 45] that, despite differences in the
clinical presentation, a common pathogenetic mecha-markers of bone turnover, and urine calcium excretion.
Calcitriol is a potent stimulator of osteoclast formation nism may account for the several subtypes of idiopathic
hypercalciuria in ICN, which represents an epiphenome-in vitro as well in vivo [31–33], while PGE2 is an impor-
tant factor of bone resorption directly or by the activa- non of a systemic disturbance in calcium metabolism.
Finally, in addition to the investigations of the yettion of 1,25-Vit D synthesis [34, 35]. On the other hand,
it was reported that calcitriol may induce interleukin-1 unknown origin of the anomalous phospholipid AA level,
to which genetic and nutritional/environmental factors(IL-1) osteoblastic receptor expression [36], and AA can
modulate the synthesis of cytokines and growth factors seem to contribute [1], the positive and long-term effects
of polyunsaturated fatty acid administration on the meta-[37, 38], well-known important local factors that are also
involved in bone remodeling [39–41]. IL-1 and tumor bolic and clinical features of ICN patients and the natural
history of this renal disease need further clinical verifica-necrosis factor-a (TNF-a) are among the most powerful
stimulators of bone resorption and are well-recognized tion. In this regard, it is worth noting that Eskimos, who
eat a v-3 fatty acid-rich diet and seem to have a veryinhibitors of bone formation. The notion of a link be-
tween AA and bone turnover seems to be confirmed by low desaturase activity [46], the rate-limiting step in the
biosynthetic pathway of highly unsaturated fatty acidsprevious findings that dietary fish oil supplementation
reduced bone turnover in an experimental animal model [47], do not generally develop nephrolithiasis. Moreover,
in studies of Japanese stone formers, it was found that[42] and decreased IL-1, IL-6, and TNF-a synthesis by
circulating monocytes [40, 43]. Moreover, preliminary the prevalence of nephrolithiasis since the Second World
War correlated positively with the increase not only inresults from our laboratory demonstrated a specific ef-
fect of AA on the genetic expression of IL-1, IL-6, and protein, but also in animal fat [48, 49]. On the other
hand, it is known that ICN emerged as a disease entityTNF-a in a human osteoblastic cell line [44].
On the whole, the results of the present study seem in Western countries at the beginning of this century,
with an expanding societal weight running parallel withto confirm the hypothesis of a close association in ICN
patients between plasma phospholipid AA levels, calcium- affluency.
regulating hormones, and urinary calcium excretion. A
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